Elisabetta Gattoni

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis

Giovanni Barosi, Gaetano Bergamaschi, Monia Marchetti et al. · Blood · 2007 · 253 citations · Full text

Medicine, Genetics, Hematology +14

A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

Alessandro Rambaldi, Chiara Maria Dellacasa, Guido Finazzi et al. · British Journal of Haematology · 2010 · 240 citations · Full text

Medicine, Hematology, Pharmacology +14

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi et al. · Cancer · 2013 · 175 citations · Full text

Medicine, Hematology, Pharmacology +14

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis

Paola Guglielmelli, Giovanni Barosi, Alessandro Rambaldi et al. · Blood · 2011 · 149 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer

M. Manzoni, B. Rovati, Monica Ronzoni et al. · Oncology · 2010 · 89 citations

Medicine, Immunology, Oncology +17